Please use this identifier to cite or link to this item: http://hdl.handle.net/11189/5785
Title: Genomic medicine and risk prediction across the disease spectrum
Authors: Kotze, Maritha. J 
Luckhoff, Hilmar. K 
Fisher, Leslie. R 
Van Der Merwe, Nicole 
Pretorius, Jacobus 
Van Velden, David. P 
Myburgh, Ettienne. J 
Pienaar, Fredrieka. M 
Van Rensburg, Susan. J 
Yako, Yandiswa 
September, Alison. V 
Moremi, Kelebogile. E 
Cronje, Frans. J 
Tiffin, Nicki 
Bouwens, Christianne. S. H 
Buizendenhout, Juanita 
Apffelstaedt, Justus. P 
Stephen, Hough. F 
Erasmus, Rajiv T 
Schneider, Johann. W 
Keywords: Breast cancer;Database;Exome;Genome;Hg19;Major allele reference sequence;Metabolic syndrome;Multiple sclerosis
Issue Date: 2015
Publisher: Critical reviews in clinical laboratory sciences
Abstract: Genomic medicine is based on the knowledge that virtually every medical condition, disease susceptibility or response to treatment is caused, regulated or influenced by genes. Genetic testing may therefore add value across the disease spectrum, ranging from single-gene disorders with a Mendelian inheritance pattern to complex multi-factorial diseases. The critical factors for genomic risk prediction are to determine: (1) where the genomic footprint of a particular susceptibility or dysfunction resides within this continuum, and (2) to what extent the genetic determinants are modified by environmental exposures. Regarding the small subset of highly penetrant monogenic disorders, a positive family history and early disease onset are mostly sufficient to determine the appropriateness of genetic testing in the index case and to inform pre-symptomatic diagnosis in at-risk family members. In more prevalent polygenic noncommunicable diseases (NCDs), the use of appropriate eligibility criteria is required to ensure a balance between benefit and risk. An additional screening step may therefore be necessary to identify individuals most likely to benefit from genetic testing. This need provided the stimulus for the development of a pathology-supported genetic testing (PSGT) service as a new model for the translational implementation of genomic medicine in clinical practice. PSGT is linked to the establishment of a research database proven to be an invaluable resource for the validation of novel and previously described gene-disease associations replicated in the South African population for a broad range of NCDs associated with increased cardio-metabolic risk. The clinical importance of inquiry concerning family history in determining eligibility for personalized genotyping was supported beyond its current limited role in diagnosing or screening for monogenic subtypes of NCDs. With the recent introduction of advanced microarray-based breast cancer subtyping, genetic testing has extended beyond the genome of the host to also include tumor gene expression profiling for chemotherapy selection. The decreasing cost of next generation sequencing over recent years, together with improvement of both laboratory and computational protocols, enables the mapping of rare genetic disorders and discovery of shared genetic risk factors as novel therapeutic targets across diagnostic boundaries. This article reviews the challenges, successes, increasing inter-disciplinary integration and evolving strategies for extending PSGT towards exome and whole genome sequencing (WGS) within a dynamic framework. Specific points of overlap are highlighted
URI: http://dx.doi.org/10.3109/10408363.2014.997930
http://hdl.handle.net/11189/5785
ISSN: 1549-781X
Appears in Collections:Edu - Journal Articles (DHET subsidised)

Show full item record

Page view(s)

41
Last Week
0
Last month
0
checked on Jul 15, 2019

Google ScholarTM

Check


This item is licensed under a Creative Commons License Creative Commons